Company profile

ObsEva SA

ObsEva is developing a novel generation of drugs addressing serious conditions compromising pregnancy from conception to birth.

ObsEva SA

Source: startup.ch

More news about ObsEva SA

05.03.2024 17:00

Business wind down and take off for listed Swiss startups
  • Financing
  • Setback
  • Success
    Please login or
    register to use the
    awards follow feature
    25.11.2022 09:57

    Obseva sells rights to its preterm labor treatment for up to $115 million
  • Financing
    Please login or
    register to use the
    awards follow feature
    24.08.2022 11:45

    Swiss biotechs in dispute with regulators
  • Setback
    Please login or
    register to use the
    awards follow feature
    20.06.2022 13:00

    Obseva receives its first European Marketing Authorization
  • Success
    Please login or
    register to use the
    awards follow feature
    06.01.2022 17:05

    ObsEva announces positive results from Phase 3 trials
  • Success
    Please login or
    register to use the
    awards follow feature
    05.08.2021 16:30

    ObsEva receives USD 500 million in upfront and milestone payments
  • Financing
    Please login or
    register to use the
    awards follow feature
    10.11.2020 15:06

    Startups under new leadership
  • Background
    Please login or
    register to use the
    awards follow feature
    08.08.2019 10:13

    ObsEva secures $75 million non-dilutive financing
  • Financing
    Please login or
    register to use the
    awards follow feature
    13.07.2018 14:08

    ObsEva with a positive start at Swiss Exchange
  • Financing
    Please login or
    register to use the
    awards follow feature
    01.03.2018 08:32

    ObsEva Reports Positive Phase 3 Results
  • Success
    Please login or
    register to use the
    awards follow feature
    02.03.2017 12:01

    Eclosion: Incubator for market stars in Geneva
  • Background
  • Support
    Please login or
    register to use the
    awards follow feature
    26.01.2017 16:52

    ObsEva goes public
  • Financing
    Please login or
    register to use the
    awards follow feature
    18.01.2017 08:20

    ObsEva Expands Leadership Team as it prepares for IPO
  • Expansion
  • Success
    Please login or
    register to use the
    awards follow feature
    31.10.2016 09:57

    ObsEva announces IPO and Phase 3 clinical trials
  • Success
    Please login or
    register to use the
    awards follow feature
    04.08.2016 16:42

    ObsEva: Fifth compound in a clinical program
  • Success
    Please login or
    register to use the
    awards follow feature
    25.02.2016 09:30

    How to raise CHF100 million
  • Background
  • Financing
    Please login or
    register to use the
    awards follow feature
    24.11.2015 16:46

    ObsEva Closes CHF 60 Million in Series B Financing
  • Financing
    Please login or
    register to use the
    awards follow feature
    11.09.2015 10:00

    ObsEva presents encouraging results of the pharmacology studies
  • Launch
    Please login or
    register to use the
    awards follow feature
    03.03.2015 08:37

    ObsEva Reports Positive Phase 1 Results for Its Lead Compound Treating Preterm Labour
  • Success
    Please login or
    register to use the
    awards follow feature
    28.11.2014 11:16

    ObsEva Announces Initiation of a Pivotal Phase 2 Study
    Please login or
    register to use the
    awards follow feature
    29.01.2014 14:04

    New Chairperson of the Board at ObsEva
    Please login or
    register to use the
    awards follow feature
    29.08.2013 15:35

    ObsEva SA announces CHF 32 Million funding
    Please login or
    register to use the
    awards follow feature
    ObsEva SA

    Founded
    2012

    Kanton
    GE


    LinkedIn

    Homepage

    rss